Treatment News : A Reduced Dose of Sustiva Proves Successful

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » July 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


July 12, 2013

A Reduced Dose of Sustiva Proves Successful

Sustiva (efavirenz), which is one of the most commonly prescribed antiretrovirals, is both safe and just as effective at fighting HIV when the standard dose is reduced by a third, MedPage Today reports. Investigators conducted a randomized controlled trial of 630 treatment-naive HIV-positive participants in 13 countries around the globe, who were given either the standard 600-milligram daily dose of Sustiva or 400 mg per day, along with a standard background regimen of Truvada (tenofovir and emtricitabine). (Together, these three drugs are the components of the single-pill, once-a-day triple combination first-line therapy Atripla.) Researchers reported their findings at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

After 48 weeks, there was no significant difference between the two arms of the study in terms of the proportion that reached a viral load of less than 200: 94 percent of those taking the smaller dose and 92 percent of those taking the larger dose reached this endpoint. (While in the United States the standard cut-off for defining a viral load as undetectable is 50, in some sites where the study was conducted they only had the capacity to test for as low as 200, so that was established as the standard in this study.)

Reducing the dose of Sustiva also did not change the number of adverse events or improve tolerability. But fewer people stopped treatment because of central nervous system reactions in the lower-dose arm.

In theory, this new finding may lead to a reduction both in the standard dosing of the drug and the cost.

Also at the IAS conference, the World Health Organization recommended Sustiva as a component of the preferred first-line HIV therapy in its new guidelines stipulating that anyone with 500 or fewer CD4 cells should begin treatment.

To read the MedPage Today story, click here.

To read the conference abstract, click here.

Search: Sustiva, efavirenz, MedPage Today, reduced dose, Truvada, tenofovir, emtricitabine, Atripla, World Health Organization, 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, IAS 2013.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.